Inside the body: study reveals how wegovy and mounjaro change your metabolism over 6 months.
NCT ID NCT07041983
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tracks 30 adults with obesity who are starting anti-obesity medications like Wegovy or Mounjaro. Researchers will measure how these drugs affect 24-hour energy expenditure and body composition (fat vs. muscle) over 6 months using a metabolic chamber and DXA scans. The goal is to understand the long-term metabolic changes behind weight loss.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Semaglutide (Wegovy) and Tirzepatide (Mounjaro)
What this could lead to
If successful, this could clarify how these weight-loss drugs change the body's energy use and fat loss, helping doctors personalize obesity treatment.
What could go wrong
This is a small, early-stage study with only 30 participants and no control group, so results may not apply to everyone. It measures metabolism changes, not long-term weight loss or health outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
university hospital of Pisa
Pisa, Italy